Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia

Ryan K. Shields, M. Hong Nguyen, Liang Chen, Ellen G. Press, Brian A. Potoski, Rachel V. Marini, Yohei Doi, Barry N. Kreiswirth, Cornelius J. Clancy

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

Original languageEnglish
Article numbere00883
JournalAntimicrobial agents and chemotherapy
Volume61
Issue number8
DOIs
Publication statusPublished - 08-2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia'. Together they form a unique fingerprint.

  • Cite this

    Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017). Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrobial agents and chemotherapy, 61(8), [e00883]. https://doi.org/10.1128/AAC.00883-17